Allergan Aesthetics, an AbbVie company, presented results from two single-center clinical studies of targeted skincare regimens in people taking medical weight loss medications, including GLP-1 receptor agonists, at the Science of Skin Summit in Austin, Texas on 17-20 September 2026.

The drugs in question are the GLP-1 receptor agonists now used widely for obesity and type 2 diabetes. Rapid weight loss has given the aesthetics industry a new commercial problem to solve, namely what happens to facial and body skin when the tissue underneath it disappears quickly, and Allergan is positioning topical regimens and its DiamondGlow dermabrasion device as the answer.

What the two studies tested

One study ran 12 weeks on a skincare regimen alone: a growth factor serum, a neck cream, and a firming and toning body lotion. The other ran six weeks and combined the same topical care with DiamondGlow treatments.

Allergan reports investigator-assessed, statistically significant improvements in selected skin quality measures across the face, neck, upper inner arms and distal thighs. Changes were observed as early as week two in the 12-week study, and immediately after treatment in the DiamondGlow arm.

The number that matters is the enrollment

Nine participants completed the 12-week protocol. Eleven had at least one post-treatment assessment in the six-week study.

That is the whole evidence base, from single-center studies run by the company that sells the products. Statistical significance in a group of nine is not the same claim as statistical significance in a group of nine hundred, and the distinction tends to vanish by the time a result reaches a product page.

The self-reported years

Participants said their facial skin looked roughly 10 years younger after four weeks of twice-daily serum use, and about 7.5 years younger after three DiamondGlow treatments plus six weeks of topical care. These are perception figures reported by participants who knew what they were using, not blinded assessments.

Satisfaction scores are legitimate data about how people feel, and they are also the easiest number in aesthetics research to move. Worth separating from the investigator-assessed measures rather than reading both as one finding.

Bottom line

Allergan itself calls these early data and says additional research in larger populations is needed, which is the correct framing and worth holding onto as the marketing catches up. The question of how GLP-1 weight loss affects skin quality is a real one, and these two small studies are a starting point rather than an answer.